drugset / Trial / NCT07216001
Role of Omega-DEK in Childhood Apraxia of Speech
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a 20-week study for children between 3 and 6 years old with confirmed childhood apraxia of speech (CAS). The study includes a 12-week open-label pilot feasibility study of an investigational drug (Omega-DEK) plus L-carnitine (Carnitor®), which is followed by an 8-week randomized, placebo-controlled discontinuation period among the same study participants.
Timeline
- Start
- 2026-05
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omega-DEK | Unknown | — | — |
| Background | L-carnitine | Other / unclassified | 2.5 ml | Oral |
| Background | L-carnitine | Other / unclassified | 250 mg | Oral |